Ultrasound and microbubbles for the treatment of ocular diseases: From preclinical research towards clinical application

Charis Rousou; Carl C.L. Schuurmans; Arto Urtti; Enrico Mastrobattista; Gert Storm; Chrit Moonen; Kai Kaarniranta; Roel Deckers

doi:10.3390/pharmaceutics13111782

Ultrasound and microbubbles for the treatment of ocular diseases: From preclinical research towards clinical application

Charis Rousou^*
, Carl C.L. Schuurmans
, Arto Urtti
, Enrico Mastrobattista
, Gert Storm
, Chrit Moonen
, Kai Kaarniranta
, Roel Deckers

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

19 Citations (Scopus)

159 Downloads (Pure)

Abstract

The unique anatomy of the eye and the presence of various biological barriers make efficacious ocular drug delivery challenging, particularly in the treatment of posterior eye diseases. This review focuses on the combination of ultrasound and microbubbles (USMB) as a minimally invasive method to improve the efficacy and targeting of ocular drug delivery. An extensive overview is given of the in vitro and in vivo studies investigating the mechanical effects of ultrasound-driven microbubbles aiming to: (i) temporarily disrupt the blood–retina barrier in order to enhance the delivery of systemically administered drugs into the eye, (ii) induce intracellular uptake of anticancer drugs and macromolecules and (iii) achieve targeted delivery of genes, for the treatment of ocular malignancies and degenerative diseases. Finally, the safety and tolerability aspects of USMB, essential for the translation of USMB to the clinic, are discussed.

Original language	English
Article number	1782
Journal	Pharmaceutics
Volume	13
Issue number	11
DOIs	https://doi.org/10.3390/pharmaceutics13111782
Publication status	Published - Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Blood–retina barrier
Cellular drug delivery
Drug delivery
Microbubble
Ocular drug delivery
Ultrasound
USMB

Access to Document

10.3390/pharmaceutics13111782Licence: CC BY

pharmaceutics-13-01782Final published version, 8.6 MBLicence: CC BY

Cite this

@article{c1200efe432d47ea8479ca3758df08ff,

title = "Ultrasound and microbubbles for the treatment of ocular diseases: From preclinical research towards clinical application",

abstract = "The unique anatomy of the eye and the presence of various biological barriers make efficacious ocular drug delivery challenging, particularly in the treatment of posterior eye diseases. This review focuses on the combination of ultrasound and microbubbles (USMB) as a minimally invasive method to improve the efficacy and targeting of ocular drug delivery. An extensive overview is given of the in vitro and in vivo studies investigating the mechanical effects of ultrasound-driven microbubbles aiming to: (i) temporarily disrupt the blood–retina barrier in order to enhance the delivery of systemically administered drugs into the eye, (ii) induce intracellular uptake of anticancer drugs and macromolecules and (iii) achieve targeted delivery of genes, for the treatment of ocular malignancies and degenerative diseases. Finally, the safety and tolerability aspects of USMB, essential for the translation of USMB to the clinic, are discussed.",

keywords = "Blood–retina barrier, Cellular drug delivery, Drug delivery, Microbubble, Ocular drug delivery, Ultrasound, USMB",

author = "Charis Rousou and Schuurmans, \{Carl C.L.\} and Arto Urtti and Enrico Mastrobattista and Gert Storm and Chrit Moonen and Kai Kaarniranta and Roel Deckers",

note = "Funding Information: This research was funded by the European Union?s Horizon 2020 research and innovation program under the Marie Sk?odowska-Curie grant agreement No. 722717. The authors thank Megan Breuer for critical proofreading of the manuscript. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = nov,

doi = "10.3390/pharmaceutics13111782",

language = "English",

volume = "13",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "MDPI",

number = "11",

}

TY - JOUR

T1 - Ultrasound and microbubbles for the treatment of ocular diseases

T2 - From preclinical research towards clinical application

AU - Rousou, Charis

AU - Schuurmans, Carl C.L.

AU - Urtti, Arto

AU - Mastrobattista, Enrico

AU - Storm, Gert

AU - Moonen, Chrit

AU - Kaarniranta, Kai

AU - Deckers, Roel

N1 - Funding Information: This research was funded by the European Union?s Horizon 2020 research and innovation program under the Marie Sk?odowska-Curie grant agreement No. 722717. The authors thank Megan Breuer for critical proofreading of the manuscript. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/11

Y1 - 2021/11

N2 - The unique anatomy of the eye and the presence of various biological barriers make efficacious ocular drug delivery challenging, particularly in the treatment of posterior eye diseases. This review focuses on the combination of ultrasound and microbubbles (USMB) as a minimally invasive method to improve the efficacy and targeting of ocular drug delivery. An extensive overview is given of the in vitro and in vivo studies investigating the mechanical effects of ultrasound-driven microbubbles aiming to: (i) temporarily disrupt the blood–retina barrier in order to enhance the delivery of systemically administered drugs into the eye, (ii) induce intracellular uptake of anticancer drugs and macromolecules and (iii) achieve targeted delivery of genes, for the treatment of ocular malignancies and degenerative diseases. Finally, the safety and tolerability aspects of USMB, essential for the translation of USMB to the clinic, are discussed.

AB - The unique anatomy of the eye and the presence of various biological barriers make efficacious ocular drug delivery challenging, particularly in the treatment of posterior eye diseases. This review focuses on the combination of ultrasound and microbubbles (USMB) as a minimally invasive method to improve the efficacy and targeting of ocular drug delivery. An extensive overview is given of the in vitro and in vivo studies investigating the mechanical effects of ultrasound-driven microbubbles aiming to: (i) temporarily disrupt the blood–retina barrier in order to enhance the delivery of systemically administered drugs into the eye, (ii) induce intracellular uptake of anticancer drugs and macromolecules and (iii) achieve targeted delivery of genes, for the treatment of ocular malignancies and degenerative diseases. Finally, the safety and tolerability aspects of USMB, essential for the translation of USMB to the clinic, are discussed.

KW - Blood–retina barrier

KW - Cellular drug delivery

KW - Drug delivery

KW - Microbubble

KW - Ocular drug delivery

KW - Ultrasound

KW - USMB

UR - https://www.scopus.com/pages/publications/85117923858

U2 - 10.3390/pharmaceutics13111782

DO - 10.3390/pharmaceutics13111782

M3 - Review article

AN - SCOPUS:85117923858

SN - 1999-4923

VL - 13

JO - Pharmaceutics

JF - Pharmaceutics

IS - 11

M1 - 1782

ER -

Ultrasound and microbubbles for the treatment of ocular diseases: From preclinical research towards clinical application

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this